

# **Diabetes Drug Market, Oral (DPP IV Inhibitor, SGLT-2, Alpha Glucosidase Inhibitor, Biguanide) Injection (Glucagon-like peptide (GLP) 1 agonist, Amylin Receptor Agonist), Insulin (Rapid – Acting Insulin, Long Acting Insulin, Premixed Insulin), Regions (United States, Europe, Japan, China, India, Brazil), Companies (Novo Nordisk, Merck & Co, Eli Lilly, AstraZeneca, Johnson & Johnson, Boehringer Ingelheim)**

<https://marketpublishers.com/r/DCAD7122A55EN.html>

Date: November 2018

Pages: 0

Price: US\$ 1,990.00 (Single User License)

ID: DCAD7122A55EN

## **Abstracts**

Global diabetes drug market is expected to surpass US\$ 76 Billion by the end of year 2024. Rising global diabetes prevalence like Type 1 diabetes and Type 2 diabetes is the major reason for growth of diabetes drug market. Type 2 diabetes is on the rise globally due to growth in obesity trends, sedentary lifestyle and lack of physical activity. Type 1 diabetes patient requires less amount diabetes drug, whereas Type 2 diabetes patient are massive consumer of diabetes drug. Several companies are creating their diabetes drug pipeline and trying to broaden their diabetes drug portfolio which will further boost the global diabetes drug market in forecast period.

Diabetes is condition in which the patient has a high blood sugar level over a long drawn period. There are 3 types of diabetes Type 1 diabetes, Type 2 diabetes and Gestational diabetes. Type 1 diabetes is a condition in which patient pancreas fail to produce enough insulin. It is also called juvenile diabetes. In Type 2 diabetes body cells fails to respond to insulin properly. Third one is Gestational diabetes in which a pregnant woman with no history of diabetes develops high blood sugar level. Globally 90% of the diabetes patients are Type 2 and rest are Type 1 cases.

Renub Research report titled “Diabetes Drug Market, Oral (DPP IV Inhibitor, SGLT-2, Alpha Glucosidase Inhibitor, Biguanide) Injection (Glucagon-like peptide (GLP) 1 agonist, Amylin Receptor Agonist), Insulin (Rapid – Acting Insulin, Long Acting Insulin, Premixed Insulin), Regions (United States, Europe, Japan, China, India, Brazil), Companies (Novo Nordisk, Merck & Co, Eli Lilly, AstraZeneca, Johnson & Johnson, Boehringer Ingelheim)” provides a complete analysis of Diabetes Drug Market.

Type 2 Diabetes Patients has bigger Consumer Base

In this report, we have categorized the diabetes drug market into two part; type 1 diabetes drug market and type 2 diabetes drug markets. (DPP) IV Inhibitor Segment has the largest Market in Global Diabetes Drug Market

According to Renub Research this report provides in-depth analysis of diabetes drug market form multiple perspectives. Here the global diabetes drug market has been categorized into 3 segments: Oral Diabetes Drug Market, Injectable Diabetes Drug Market and Insulin.

Oral Diabetes Drug Market is further sub-divided into 5 categories by drug class- (DPP) IV Inhibitor, SGLT-2, Alpha Glucosidase Inhibitor, Biguanide and Other Oral Drug market.

Injectable Diabetes Drug Market has been further classified into 2 parts - Glucagon-like peptide (GLP) 1 agonist and Amylin receptor agonist market.

Insulin Market has been further categorized into 4 parts - Rapid – Acting Insulin market, Long Acting Insulin market, Premixed Insulin market and Other Insulin market.

United States dominates the Global diabetes drug Market

The regions covered in the report for of type 1 diabetes drug market are United States, European Union (France, Germany, Italy, Spain and United Kingdom), Japan and Canada.

The regions covered for type 2 diabetes drug market - are United States, European Union (France, Germany, Italy, Spain and United Kingdom), Japan, China, India and

Brazil. In addition, we have also covered diabetes population of each of these covered regions along with Type 1 and Type 2 diabetes populations.

## Novo Nordisk is the Largest Player in Global Diabetes Drug Market

In this report, published by Renub Research a comprehensive assessment of global diabetes drug revenue by five major key players is covered. The key players covered in the report are Novo Nordisk, Merck & Co, Eli Lilly, AstraZeneca, Johnson & Johnson and Boehringer Ingelheim. This report covers historical sales analysis and forecast along with major factors like diabetes R&D and pipeline of diabetes drug in separate chapter.

## Disease Type - Global Diabetes Drug Market

1. By Type 1 Diabetes Drug Market
2. By Type 2 Diabetes Drug Market

## Product - Global Diabetes Drug Market

### Oral

1. (DPP) IV inhibitor
2. SGLT-2
3. Alpha Glucosidase Inhibitor
4. Biguanide
5. Others Oral Drug

### Injection

1. Glucagon-like peptide (GLP) 1 agonist
2. Amylin receptor agonist

### Insulin

1. Rapid – Acting Insulin
2. Long Acting Insulin
3. Premixed Insulin
4. Other Insulin

## Regions - Population Type 1 & Type 2 Diabetes Drug

1. United States
2. 5 European Union (France, Germany, Italy, Spain and United Kingdom)
3. Japan
4. China
5. India
6. Brazil

## Regions - Type 1 Diabetes Drug Market

1. United States
2. 5 European Union (France, Germany, Italy, Spain and United Kingdom)
3. Japan
4. Canada

## Regions - Type 2 Diabetes Drug Market

1. United States
2. 5 European Union (France, Germany, Italy, Spain and United Kingdom)
3. Japan
4. China
5. India
6. Brazil

## Key Players Analysis

1. Novo Nordisk
2. Merck & Co
3. Eli Lilly
4. AstraZeneca
5. Johnson & Johnson
6. Boehringer Ingelheim

## Contents

### **1. INTRODUCTION**

- 1.1 Market Definition
- 1.2 Currency Conversion

### **2. RESEARCH METHODOLOGY**

### **3. EXECUTIVE SUMMARY**

### **4. GLOBAL DIABETES DRUG MARKET**

### **5. MARKET SHARE – GLOBAL DIABETES DRUG**

- 5.1 Disease Type
- 5.2 Therapy – (Oral, Injection, Insulin)
- 5.3 Oral Drug
- 5.4 Injection Drug
- 5.5 Insulin
- 5.6 Regions – Type 1 Diabetes Drug
- 5.7 Regions – Type 2 Diabetes Drug

### **6. DISEASE TYPE – GLOBAL DIABETES DRUG MARKET**

- 6.1 Type 1 Diabetes
- 6.2 Type 2 Diabetes

### **7. THERAPY – GLOBAL DIABETES DRUG MARKET**

- 7.1 Oral Drugs Market
  - 7.1.1 (DPP) IV Inhibitor
  - 7.1.2 SGLT-2
  - 7.1.3 Alpha Glucosidase Inhibitor
  - 7.1.4 Biguanide
  - 7.1.5 Others Oral Drug
- 7.2 Injectable Drugs Market
  - 7.2.1 Glucagon-like peptide (GLP) 1 agonist
  - 7.2.2 Amylin Receptor Agonist

### 7.3 Insulin Market

7.3.1 Rapid – Acting Insulin

7.3.2 Long Acting Insulin

7.3.3 Premixed Insulin

7.3.4 Other Insulin

## **8. REGION – TYPE 1 DIABETES DRUG MARKET**

8.1 United States

8.2 European Union

8.3 Japan

8.4 Canada

## **9. REGION – TYPE 2 DIABETES DRUG MARKET**

9.1 United States

9.2 European Union

9.3 Japan

9.4 China

9.5 India

9.6 Brazil

## **10. REGIONS – DIABETIC POPULATION**

10.1 United States

10.1.1 Type

10.1.2 Type

10.2 European Union

10.2.1 Type

10.2.2 Type

10.3 Japan

10.3.1 Type

10.3.2 Type

10.4 Canada

10.4.1 Type

10.4.2 Type

10.5 China

10.5.1 Type

10.6 India

- 10.6.1 Type
- 10.7 Brazil
  - 10.7.1 Type

## **11. KEY PLAYERS ANALYSIS**

- 11.1 Novo Nordisk Overview
  - 11.1.1 R&D Pipeline
  - 11.1.2 Sales Analysis
- 11.2 Merck & Co Overview
  - 11.2.1 R&D Pipeline
  - 11.2.2 Sales Analysis
- 11.3 Eli Lilly Overview
  - 11.3.1 R&D Pipeline
  - 11.3.2 Sales Analysis
- 11.4 AstraZeneca Overview
  - 11.4.1 R&D Pipeline
  - 11.4.2 Sales Analysis
- 11.5 Johnson & Johnson Overview
  - 11.5.1 R&D Pipeline
  - 11.5.2 Sales Analysis
- 11.6 Boehringer Ingelheim Overview
  - 11.6.1 R&D Pipeline
  - 11.6.2 Sales Analysis

## **12. MERGERS & ACQUISITIONS**

## **13. MARKET DYNAMICS**

- 13.1 Growth Drivers
  - 13.1.1 Rising Prevalence of Diabetes
  - 13.1.2 Rising Cost of Diabetes Care
- 13.2 Challenges
  - 13.2.1 Controversy regarding Clinical Benefits
- 13.3 Opportunities

## List Of Figures

### LIST OF FIGURES:

- Figure-01: Global – Diabetes Drugs Market size (Million US\$), 2018 & 2024
- Figure-02: Global – Diabetes Drugs Growing Segments
- Figure-03: Global – Diabetes Drugs Market (Million US\$), 2016 – 2017
- Figure-04: Global – Forecast for Diabetes Drugs Market(Million US\$), 2018 – 2024
- Figure-05: Global – Diabetes Drugs Market Share by Disease type (Percent), 2016 – 2017
- Figure-06: Global – Forecast for Diabetes Drugs Market Share by disease type(Percent), 2018 – 2024
- Figure-07: Global – Diabetes Drugs Market Share by Therapy (Percent), 2016 – 2017
- Figure-08: Global – Forecast for Diabetes Drugs Market Share by Therapy (Percent), 2018 – 2024
- Figure-09: Global – Diabetes Drugs Market Share by Oral Drug (Percent), 2016 – 2017
- Figure-10: Global – Forecast for Diabetes Drugs Market Share by Oral Drug (Percent), 2018 – 2024
- Figure-11: Global – Diabetes Drugs Market Share by Injectable Drug (Percent), 2016 – 2017
- Figure-12: Global – Forecast for Diabetes Drugs Market Share by Injectable Drug (Percent), 2018 – 2024
- Figure-13: Global – Diabetes Drugs Market Share by Insulin (Percent), 2016 – 2017
- Figure-14: Global – Forecast for Diabetes Drugs Market Share by Insulin (Percent), 2018 – 2024
- Figure-15: Global – Diabetes Drugs Market Share type1 Diabetes Drug by Regions (Percent), 2016 – 2017
- Figure-16: Global – Forecast for Diabetes Drugs Market Share type1 Diabetes Drug by Regions (Percent), 2018 – 2024
- Figure-17: Global – Diabetes Drugs Market Share type2 Diabetes Drug by Regions (Percent), 2016 – 2017
- Figure-18: Global – Forecast for Diabetes Drugs Market Share type2 Diabetes Drug by Regions (Percent), 2018 – 2024
- Figure-19: Global – Diabetes Drug Market by type1 Diabetes (Million US\$), 2016 – 2017
- Figure-20: Global – Forecast for Diabetes Drug Market by type1 Diabetes (Million US\$), 2018 – 2024
- Figure-21: Global – Diabetes Drug Market by type2 Diabetes (Million US\$), 2016 – 2017
- Figure-22: Global – Forecast for Diabetes Drug Market by type2 Diabetes (Million US\$), 2018 – 2024



Figure-23: Global – Oral Drug (DPP) IV inhibitor Market (Million US\$), 2016 – 2017

Figure-24: Global – Forecast for Oral Drug (DPP) IV inhibitor Market (Million US\$), 2018 – 2024

Figure-25: Global – Oral Drug SGLT-2 Market (Million US\$), 2016 – 2017

Figure-26: Global – Forecast for Oral Drug SGLT-2 Market (Million US\$), 2018 – 2024

Figure-27: Global – Oral Drug Alpha Glucosidase Inhibitor Market (Million US\$), 2016 – 2017

Figure-28: Global – Forecast for Oral Drug Alpha glucosidase inhibitor Market (Million US\$), 2018 – 2024

Figure-29: Global – Oral Drug Biguanide Market (Million US\$), 2016 – 2017

Figure-30: Global – Forecast for Oral Drug Biguanide Market (Million US\$), 2018 – 2024

Figure-31: Global – Oral Drug Others Market (Million US\$), 2016 – 2017

Figure-32: Global – Forecast for Oral Drug Others Market (Million US\$), 2018 – 2024

Figure-33: Global – Diabetes Injectable Drug Glucagon-like peptide (GLP) 1 agonist Market (Million US\$), 2016 – 2017

Figure-34: Global – Forecast for Diabetes Injectable Drug Glucagon-like peptide (GLP) 1 agonist Market (Million US\$), 2018 – 2024

Figure-35: Global – Diabetes Injectable Drug Amylin receptor agonist Market (Million US\$), 2016 – 2017

Figure-36: Global – Forecast for Diabetes Injectable Drug Amylin receptor agonist Market (Million US\$), 2018 – 2024

Figure-37: Global – Diabetes Insulin Drug Rapid Acting (Fast Acting) Market (Million US\$), 2016 – 2017

Figure-38: Global – Forecast for Diabetes Insulin Drug Rapid Acting (Fast Acting) Market (Million US\$), 2018 – 2024

Figure-39: Global – Diabetes Insulin Drug Long Acting Market (Million US\$), 2016 – 2017

Figure-40: Global – Forecast for Diabetes Insulin Drug Long Acting Market (Million US\$), 2018 – 2024

Figure-41: Global – Diabetes Insulin Drug Premixed Market (Million US\$), 2016 – 2017

Figure-42: Global – Forecast for Diabetes Insulin Drug Premixed Market (Million US\$), 2018 – 2024

Figure-43: Global – Diabetes Drug Other Insulin (Including Human Insulin) Market (Million US\$), 2016 – 2017

Figure-44: Global – Forecast for Diabetes Drug Other Insulin (Including Human Insulin) Market (Million US\$), 2018 – 2024

Figure-45: United States – type1 Diabetes Drug Market (Million US\$), 2016 – 2017

Figure-46: United States – Forecast for Type1 Diabetes Drug Market (Million US\$), 2018 – 2024

Figure-47: 5 European Union – type 1 Diabetes Drug Market (Million US\$), 2016 – 2017

Figure-48: 5 European Union – Forecast for type 1 Diabetes Drug Market (Million US\$), 2018 – 2024

Figure-49: Japan – type1 Diabetes Drug Market (Million US\$), 2016 – 2017

Figure-50: Japan – Forecast for type1 Diabetes Drug Market (Million US\$), 2018 – 2024

Figure-51: Canada – type 1 Diabetes Drug Market (Million US\$), 2016 – 2017

Figure-52: Canada – Forecast for type1 Diabetes Drug Market (Million US\$), 2018 – 2024

Figure-53: United States – type2 Diabetes Drug Market (Million US\$), 2016 – 2017

Figure-54: United States – Forecast for type2 Diabetes Drug Market (Million US\$), 2018 – 2024

Figure-55: 5 European Union – type2 Diabetes Drug Market (Million US\$), 2016 – 2017

Figure-56: 5 European Union – Forecast for type2 Diabetes Drug Market (Million US\$), 2018 – 2024

Figure-57: Japan – type2 Diabetes Drug Market (Million US\$), 2016 – 2017

Figure-58: Japan – Forecast for type2 Diabetes Drug Market (Million US\$), 2018 – 2024

Figure-59: China – type2 Diabetes Drug Market (Million US\$), 2016 – 2017

Figure-60: China – Forecast for type2 Diabetes Drug Market (Million US\$), 2018 – 2024

Figure-61: India – type2 Diabetes Drug Market (Million US\$), 2016 – 2017

Figure-62: India – Forecast for type2 Diabetes Drug Market (Million US\$), 2018 – 2024

Figure-63: Brazil – type2 Diabetes Drug Market (Million US\$), 2016 – 2017

Figure-64: Brazil – Forecast for type2 Diabetes Drug Market (Million US\$), 2018 – 2024

Figure-65: United States – Diabetes Population (Thousands), 2010 – 2017

Figure-66: United States – Forecast for Diabetes Population (Thousands), 2018 – 2024

Figure-67: United States – type1 Diabetes Population (Thousands), 2010 – 2017

Figure-68: United States – Forecast for type1 Diabetes Population (Thousands), 2018 – 2024

Figure-69: United States – type2 Diabetes Population (Thousands), 2010 – 2017

Figure-70: United States – Forecast for type2 Diabetes Population (Thousands), 2018 – 2024

Figure-71: European Union – Diabetes Population (Thousands), 2010 – 2017

Figure-72: European Union – Forecast for Diabetes Population (Thousands), 2018 – 2024

Figure-73: 5 European Union – type1 Diabetes Population (Thousands), 2010 – 2017

Figure-74: 5 European Union – Forecast for type1 Diabetes Population (Thousands), 2018 – 2024

Figure-75: European Union – type2 Diabetes Population (Thousands), 2010 – 2017

Figure-76: European Union – Forecast for type2 Diabetes Population (Thousands), 2018 – 2024

- Figure-77: Japan – Diabetes Population (Thousands), 2010 – 2017
- Figure-78: Japan – Forecast for Diabetes Population (Thousands), 2018 – 2024
- Figure-79: Japan – Type1 Diabetes Population (Thousands), 2010 – 2017
- Figure-80: Japan – Forecast for type1 Diabetes Population (Thousands), 2018 – 2024
- Figure-81: Japan – Type2 Diabetes Population (Thousands), 2010 – 2017
- Figure-82: Japan – Forecast for Type2 Diabetes Population (Thousands), 2018 – 2024
- Figure-83: Canada – Diabetes Population (Thousands), 2010 – 2017
- Figure-84: Canada – Forecast for Diabetes Population (Thousands), 2018 – 2024
- Figure-85: Canada – type1 Diabetes Population (Thousands), 2010 – 2017
- Figure-86: Canada – Forecast for type1 Diabetes Population (Thousands), 2018 – 2024
- Figure-87: China – type2 Diabetes Population (Thousands), 2010 – 2017
- Figure-88: China – Forecast for type2 Diabetes Population (Thousands), 2018 – 2024
- Figure-89: India – type2 Diabetes Population (Thousands), 2010 – 2017
- Figure-90: India – Forecast for type2 Diabetes Population (Thousands), 2018 – 2024
- Figure-91: Brazil – Diabetes Population (Thousands), 2010 – 2017
- Figure-92: Brazil – Forecast for Diabetes Population (Thousands), 2018 – 2024
- Figure-93: Global – Novo Nordisk Diabetes Drug Sales (Million US\$), 2015 – 2017
- Figure-94: Global – Forecast for Novo Nordisk Diabetes Drug Sales (Million US\$), 2018 – 2024
- Figure-95: Global – Merck & Co Diabetes Drug Sales (Million US\$), 2015 – 2017
- Figure-96: Global – Forecast for Merck & Co Diabetes Drug Sales (Million US\$), 2018 – 2024
- Figure-97: Global – Eli Lilly Diabetes Drug Sales (Million US\$), 2015 – 2017
- Figure-98: Global – Forecast for Eli Lilly Diabetes Drug Sales (Million US\$), 2018 – 2024
- Figure-99: Global – AstraZeneca Diabetes Drug Sales (Million US\$), 2015 – 2017
- Figure-100: Global – Forecast for AstraZeneca Diabetes Drug Sales (Million US\$), 2018 – 2024
- Figure-101: Global – Johnson & Johnson Diabetes Drug Sales (Million US\$), 2015 – 2017
- Figure-102: Global – Forecast for Johnson & Johnson Diabetes Drug Sales (Million US\$), 2018 – 2024
- Figure-103: Global – Boehringer Ingelheim Diabetes Drug Sales (Million US\$), 2015 – 2017
- Figure-104: Global – Forecast for Boehringer Ingelheim Diabetes Drug Sales (Million US\$), 2018 – 2024

## I would like to order

Product name: Diabetes Drug Market, Oral (DPP IV Inhibitor, SGLT-2, Alpha Glucosidase Inhibitor, Biguanide) Injection (Glucagon-like peptide (GLP) 1 agonist, Amylin Receptor Agonist), Insulin (Rapid – Acting Insulin, Long Acting Insulin, Premixed Insulin), Regions (United States, Europe, Japan, China, India, Brazil), Companies (Novo Nordisk, Merck & Co, Eli Lilly, AstraZeneca, Johnson & Johnson, Boehringer Ingelheim)

Product link: <https://marketpublishers.com/r/DCAD7122A55EN.html>

Price: US\$ 1,990.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DCAD7122A55EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970